Rigel Pharma (RIGL) Misses Q4 EPS by 2c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Rigel Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
February 27, 2020 4:01 PM ESTSOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2019, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets, for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
"We are entering 2020 with a clear plan to drive shareholder value for Rigel," said Raul Rodriguez, Rigel's president and CEO. "We see substantial opportunities for TAVALISSE to meet patient needs in the growing adult chronic ITP... More
